In a case that underscores the strategic complexity of pharmaceutical patent litigation, Mylan NV voluntarily dismissed — without prejudice — its infringement action against Bayer AG and Janssen Pharmaceuticals, Inc. before reaching a merits ruling. Filed on May 19, 2023, and closed just 300 days later on March 14, 2024, Case No. 1:23-cv-00556 in the U.S. District Court for the District of Delaware centered on U.S. Patent No. 9,415,053 B2, covering a solid, orally administrable pharmaceutical composition.

The voluntary dismissal without prejudice is itself a significant procedural event — it preserves Mylan’s right to refile, signals potential parallel litigation or licensing negotiations, and raises important questions about pharmaceutical patent enforcement strategies. For patent attorneys, in-house IP counsel, and R&D teams operating in the branded and generic drug space, this case offers instructive lessons about litigation timing, venue strategy, and the calculated use of Rule 41 dismissals as a tactical instrument.

Case Overview

The Parties

The Patent at Issue

This case involved U.S. Patent No. 9,415,053 B2 (Application No. 14/250,863) which covers a **solid, orally administrable pharmaceutical composition**. Patents of this class typically protect formulation innovations—including drug release profiles, excipient combinations, bioavailability enhancements, or dosage form structures—that extend commercial protection beyond the compound patent itself.

• • US 9,415,053 B2 — Solid, orally administrable pharmaceutical composition

The Accused Product

The accused product falls within the category of solid oral pharmaceutical compositions. Given Bayer and Janssen’s joint involvement, this likely implicates a co-promoted or co-developed branded therapy, potentially in the cardiovascular or hematology space where both companies hold significant shared commercial interests.

Legal Representation

Plaintiff Mylan was represented by Potter Anderson & Corroon, LLP, with attorneys Andrew L. Brown, Bindu Ann George Palapura, David Ellis Moore, Elham F. Steiner, Tung-On Kong, Ty W. Callahan, and Wendy L. Devine. Defendants Bayer AG and Janssen were represented by Morris, Nichols, Arsht & Tunnell LLP, through Derek James Fahnestock and Rodger Dallery Smith II. The presence of two elite Delaware firms signals the commercial significance both sides placed on this dispute.

Litigation Timeline & Procedural History

Mylan filed the complaint in the U.S. District Court for the District of Delaware — the nation’s preeminent venue for pharmaceutical patent disputes, particularly those arising from Hatch-Waxman Paragraph IV certification challenges or independent infringement theories. Delaware’s concentration of patent-specialized judges, predictable procedural timelines, and favorable docket management make it the default choice for pharmaceutical IP actions of this complexity.

The case was presided over by Chief Judge Richard G. Andrews, an experienced Delaware jurist with a substantial patent litigation docket. His familiarity with pharmaceutical IP cases would have made claim construction and dispositive motion practice highly informed. The case resolved at the first-instance (district court) level, before trial, through Mylan’s invocation of Federal Rule of Civil Procedure 41(a)(1)(A)(i) — a unilateral voluntary dismissal filed before any answer or motion for summary judgment by the defendant triggered the need for court approval.

The 300-day duration — without reaching claim construction or summary judgment rulings — suggests the dismissal occurred during the pleadings or early discovery phase, though specific interim milestones are not disclosed in available records.

The Verdict & Legal Analysis

Outcome

Pursuant to Fed. R. Civ. P. 41(a)(1)(A)(i), Mylan voluntarily dismissed all claims without prejudice. No damages were awarded. No injunctive relief was granted or denied. The case produced no merits ruling on validity, infringement, or claim construction.

The critical legal distinction here is “without prejudice” — Mylan explicitly preserved its right to refile the same claims at a future date, subject to applicable statutes of limitations and any intervening procedural bars.

Verdict Cause Analysis

Because the dismissal was procedural rather than adjudicative, there is no judicial finding on infringement or patent validity. However, the timing and structure of the dismissal warrant careful analysis:

Rule 41(a)(1)(A)(i) permits a plaintiff to dismiss without court approval at any time before the opposing party serves an answer or a motion for summary judgment. Filing under this specific provision — rather than Rule 41(a)(2), which requires court order — indicates Mylan acted decisively and early, before defendants had formally responded to the complaint.

This is a tactically significant choice. Possible explanations include:

• • Parallel settlement or licensing negotiations that rendered litigation unnecessary or strategically counterproductive
• • Discovery concerns or claim vulnerability identified after filing that counseled withdrawal before adverse rulings
• • Business restructuring considerations given Mylan’s integration into Viatris
• • Coordination with other proceedings, such as IPR petitions at the USPTO or related litigation in other jurisdictions

Legal Significance

While this case produced no binding precedent, its procedural posture carries instructive value. A Rule 41(a)(1)(A)(i) dismissal without prejudice in a pharmaceutical patent case reminds practitioners that:

1. Litigation initiation does not commit a party to full-scale trial — early exit ramps exist and are strategically deployable
2. The Delaware District Court’s docket remains the dominant forum for resolving pharmaceutical composition patent disputes
3. Multi-defendant pharmaceutical cases (here, both Bayer AG and Janssen) require careful coordination of legal strategy across entities with overlapping but distinct IP interests

Industry & Competitive Implications

The Mylan v. Bayer AG and Janssen Pharmaceuticals litigation reflects a broader strategic pattern in pharmaceutical patent enforcement: composition-of-matter patents on solid oral dosage forms are increasingly contested as branded manufacturers seek to extend market exclusivity beyond primary compound patent expiration.

For Bayer AG and Janssen, the dismissal without prejudice means lingering uncertainty. The branded manufacturers cannot assume the threat has passed — Mylan retains the right to refile, and the patent remains a live litigation risk until it either expires, is invalidated, or a licensing resolution is reached.

For the generic pharmaceutical industry broadly, this case highlights the ongoing tension between generic entry strategies and the layered patent portfolios maintained by branded manufacturers. The use of formulation patents as secondary protection mechanisms continues to generate litigation volume in Delaware and other venues.

From a licensing and settlement perspective, the swift resolution — 300 days from filing to dismissal — may reflect a negotiated outcome that simply was not disclosed publicly, a common outcome in pharmaceutical patent disputes where commercial relationships between parties extend beyond any single litigation.